Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Therapeutic Use
- Acronyms KINECT; KINECT-1
- Sponsors Neurocrine Biosciences
- 01 Nov 2021 According to a Neurocrine Biosciences media release, results of new pooled analysis from the KINECT clinical trial program and long-term extension studies presented at the 2021 Psych Congress scientific meeting
- 01 Nov 2021 Results published in the Neurocrine Biosciences Media Release
- 27 Apr 2018 Results of a pooled analysis from KINECT, KINECT 2, and KINECT 3 studies assessing minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score in tardive dyskinesia, presented at the 70th Annual Meeting of the American Academy of Neurology